チロシンキナーゼ阻害剤の世界市場2019-2023

◆英語タイトル:Global Tyrosine Kinase Inhibitors Market 2019-2023
◆商品コード:IRTNTR30518
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月17日
◆ページ数:115
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、チロシンキナーゼ阻害剤の世界市場について調査・分析し、市場概要、市場環境、チロシンキナーゼ阻害剤市場規模、製品別(RTKI、nRTKI)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・チロシンキナーゼ阻害剤の世界市場概要
・チロシンキナーゼ阻害剤の世界市場環境
・チロシンキナーゼ阻害剤の世界市場動向
・チロシンキナーゼ阻害剤の世界市場規模
・チロシンキナーゼ阻害剤の世界市場:業界構造分析
・チロシンキナーゼ阻害剤の世界市場:製品別(RTKI、nRTKI)
・チロシンキナーゼ阻害剤の世界市場:地域別市場規模・分析
・チロシンキナーゼ阻害剤の北米市場規模・予測
・チロシンキナーゼ阻害剤のヨーロッパ・中東・アフリカ市場規模・予測
・チロシンキナーゼ阻害剤のアジア太平洋市場規模・予測
・チロシンキナーゼ阻害剤の主要国分析
・チロシンキナーゼ阻害剤の世界市場:意思決定フレームワーク
・チロシンキナーゼ阻害剤の世界市場:成長要因、課題
・チロシンキナーゼ阻害剤の世界市場:競争環境
・チロシンキナーゼ阻害剤の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Bristol-Myers Squibb、F. Hoffmann-La Roche、Johnson & Johnson、Novartis、Pfizerなどです。
【レポートの概要】

About this market
Strategic alliances to trend in the market. The growing prevalence of various diseases increases the demand for innovative therapeutics. TKI therapeutics are one of the most reliable therapeutic options for the treatment of cancer and age-related diseases such as RVO. Technavio’ s analysts have predicted that the tyrosine kinase inhibitors market will register a CAGR of more than 8% by 2023.
Market Overview
Recent approvals of TKIs
Many TKI therapeutic candidates are gaining approval due to their high safety profile and efficacy. The therapeutics that are in last stage of development are expected to get marketing approval during forecast period.
Side effects of TKIs
Despite highly efficacious, TKIs are associated with a spectrum of side effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea.
For the detailed list of factors that will drive and challenge the growth of the tyrosine kinase inhibitors market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the rising strategic alliances and the recent approvals of TKIs, will provide considerable growth opportunities to tyrosine kinase inhibitors manufactures. Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• The threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• RTKIs – Market size and forecast 2018-2023
• nRTKIs – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Johnson & Johnson
• Novartis
• Pfizer
PART 13: APPENDIX
• Research methodology
• List of abbreviations

Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: RTKIs – Market size and forecast 2018-2023 ($ billions)
Exhibit 21: RTKIs – Year-over-year growth 2019-2023 (%)
Exhibit 22: nRTKIs – Market size and forecast 2018-2023 ($ billions)
Exhibit 23: nRTKIs – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ billions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ billions)
Exhibit 32: Example of patient-assistance program for cancer treatment
Exhibit 33: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC – Market size and forecast 2018-2023 ($ billions)
Exhibit 36: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Decision framework
Exhibit 41: Reported top 5 new cases of cancer types in US in 2015
Exhibit 01: Treatment costs of TKIs
Exhibit 02: Side effects of TKIs
Exhibit 03: Impact of drivers and challenges
Exhibit 07: Vendor landscape
Exhibit 08: Landscape disruption
Exhibit 09: Vendors covered
Exhibit 10: Vendor classification
Exhibit 11: Market positioning of vendors
Exhibit 12: Bristol-Myers Squibb – Vendor overview
Exhibit 13: Bristol-Myers Squibb – Business segments
Exhibit 14: Bristol-Myers Squibb – Organizational developments
Exhibit 15: Bristol-Myers Squibb – Geographic focus
Exhibit 16: Bristol-Myers Squibb – Key offerings
Exhibit 17: Bristol-Myers Squibb – Key customers
Exhibit 18: F. Hoffmann-La Roche – Vendor overview
Exhibit 19: F. Hoffmann-La Roche – Business segments
Exhibit 20: F. Hoffmann-La Roche – Organizational developments
Exhibit 21: F. Hoffmann-La Roche – Geographic focus
Exhibit 22: F. Hoffmann-La Roche – Segment focus
Exhibit 23: F. Hoffmann-La Roche – Key offerings
Exhibit 24: F. Hoffmann-La Roche – Key customers
Exhibit 25: Johnson & Johnson – Vendor overview
Exhibit 26: Johnson & Johnson – Business segments
Exhibit 27: Johnson & Johnson – Organizational developments
Exhibit 28: Johnson & Johnson – Geographic focus
Exhibit 29: Johnson & Johnson – Segment focus
Exhibit 30: Johnson & Johnson – Key offerings
Exhibit 31: Johnson & Johnson – Key customers
Exhibit 32: Novartis – Vendor overview
Exhibit 33: Novartis – Business segments
Exhibit 34: Novartis – Organizational developments
Exhibit 35: Novartis – Geographic focus
Exhibit 36: Novartis – Segment focus
Exhibit 37: Novartis – Key offerings
Exhibit 38: Novartis – Key customers
Exhibit 39: Pfizer – Vendor overview
Exhibit 40: Pfizer – Business segments
Exhibit 41: Pfizer – Organizational developments
Exhibit 42: Pfizer – Geographic focus
Exhibit 43: Pfizer – Segment focus
Exhibit 44: Pfizer – Key offerings
Exhibit 45: Pfizer – Key customers
Exhibit 46: Validation techniques employed for market sizing
Exhibit 47: List of abbreviations



【掲載企業】

Bristol-Myers Squibb、F. Hoffmann-La Roche、Johnson & Johnson、Novartis、Pfizer

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[チロシンキナーゼ阻害剤の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆